Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 86Terminated 32Recruiting 21Active not recruiting 16Unknown 13Withdrawn 10Not yet recruiting 4Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, B-Cell 1

Interventions

pembrolizumab 3Drug Therapy 3Vincristine 2S 1 (combination) 2Nivolumab 2Gemcitabine 2Cyclophosphamide 2CA-4948 2Bevacizumab 2zimberelimab 1venetoclax 1tivozanib 1titanium silicide 1tisagenlecleucel 1sotigalimab 1propranolol CR 1prednylidene 1pimonidazole 1palbociclib 1mirdametinib 1imisopasem manganese 1gusacitinib 1fludarabine 1deltacortene 1brincidofovir 1axicabtagene ciloleucel 1atezolizumab 1Testosterone Propionate 1Testosterone 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Suspended × Rituximab × Clear all
NCT03704714 2022-08-15

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Northwestern University

Phase 1/2 Suspended
30 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡